pifithrin has been researched along with Leukemia in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sparfel, L | 1 |
| Van Grevenynghe, J | 1 |
| Le Vee, M | 1 |
| Aninat, C | 1 |
| Fardel, O | 1 |
1 other study available for pifithrin and Leukemia
| Article | Year |
|---|---|
Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin alpha.
Topics: Apoptosis; Aryl Hydrocarbon Hydroxylases; Benzo(a)pyrene; Benzothiazoles; Breast Neoplasms; Carcinog | 2006 |